Stock Price, News, Quote and Profile of STANDARD BIOTOOLS INC(NASDAQ:LAB) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

STANDARD BIOTOOLS INC

NASDAQ:LAB (9/16/2024, 8:23:02 PM)

After market: 2.09 0 (0%)

2.09

+0.03 (+1.46%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryLife Sciences Tools & Services

GICS SubIndustry

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Chartmill High Growth Momentum

EPS Q2Q%

Sales Q2Q%

CRS

6 Month-22.01%

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap775.70M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. The company is headquartered in South San Francisco, California and currently employs 534 full-time employees. The company went IPO on 2011-02-10. The firm's segments include Proteomics and Genomics. The Proteomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of genes and their functions. The firm provides insights in health and disease using its mass cytometry and microfluidics technologies, which serve applications in proteomics and genomic. The company works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories around the world, focusing on the needs in translational and clinical research, including oncology, immunology, and immunotherapy. The firm also provides differentiated multi-omics tools for research.